Condensed-Indan derivatives and pharmaceutically acceptable salt

Details Condensed-Indan derivatives and pharmaceutically acceptable salt Condensed-Indan derivatives and pharmaceutically acceptable salt

1996-01-19

1998-03-31

Shah, Mukund J.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

546 61, A61K 3147, C07D22118, C07D49156

Patent

active

057339180

DESCRIPTION:

BRIEF SUMMARY
TECHNICAL FIELD

The present invention relates to novel condensed-indan derivatives, pharmaceutically acceptable salts thereof, a method for producing the derivatives, composition and antitumor agent containing the derivatives and a method for treating tumor of mammal. The compounds of the invention have excellent antitumor activities, thereby useful as antitumor agent.


BACKGROUND ART
at 6-position by a piperazinyl group described in Med. Chem. Res., 3, 44-51 (1993) are known. Although the document discloses antiserotonin activities thereof, antitumor activities of the compounds are in no way reported and described in the document. The antitumor activities of the condensed-indan derivatives of the invention are, hence, unknown.
It is an object of the invention to provide compounds which have excellent antitumor activities and are useful as medicament for treatment of tumor.


DISCLOSURE OF THE INVENTION

The present inventors have conducted research and found that condensed-indan derivatives demonstrate excellent antitumor activities and are useful as antitumor agent. Thus, the present invention has been accomplished.
The present invention provides condensed-indan derivatives represented by the formula (1) or pharmaceutically acceptable salts thereof: ##STR2## wherein ring A represents an optionally substituted benzene ring or naphthalene ring, or a benzene ring having a lower alkylenedioxy group, ring B represents an optionally substituted benzene ring or a benzene ring having a lower alkylenedioxy group. Y represents --N.dbd.CR-- or --CR.dbd.N--, R represents a --NR.sub.1 R.sub.2 group, an optionally substituted nitrogen-containing heterocyclic group or a --OR.sub.3 group, wherein R.sub.1 and R.sub.2 are the same or different and each is a hydrogen atom; a phenyl group; an optionally substituted nitrogen-containing heterocyclic group; a lower alkyl group which may be substituted by at least one selected from the group consisting of an optionally substituted amino group, a lower alkoxy group, a phenyl group, a nitrogen-containing heterocyclic group, an amine oxide group substituted by a lower alkyl group or a hydroxyl group; R.sub.3 represents a lower alkyl group optionally substituted by a substituted amino group, provided that ring A and ring B are not a benzene ring having no substituent when R represents an optionally substituted nitrogen-containing heterocyclic group.
The compounds of the present invention represented by said formula (1) has excellent antitumor activities, and are effective for treatment of a variety of tumors.
Accordingly, the invention provides a composition comprising an effective amount of the compound of said formula (1) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier therefor.
The present invention, in particular, provides an antitumor agent comprising an effective amount of the compound of said formula (1) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier therefor.
The present invention further provides a method for treating tumor of mammal which comprises administering an effective amount of the compound of said formula (1) or a pharmaceutically acceptable salt thereof to mammal.
In said formula (1), examples of groups as defined in R.sub.1, R.sub.2 and R.sub.3 and the other groups described in the specification are shown below.
Examples of substituent groups included in benzene ring and naphthalene ring represented by ring A and ring B are halogen atom, lower alkyl group, lower alkoxy group, hydroxyl group, nitro group, amino group, lower acyloxy group, benzyloxy group, lower acylamino group, cyano group, carboxyl group, lower alkoxycarbonyl group, preferably halogen atom, lower alkyl group, lower alkoxy group, hydroxyl group, nitro group, amino group, lower acyloxy group, benzyloxy group and lower acylamino group.
Said substituent groups may be placed at any position of each ring which may have the same or different 1-4 substituent groups. With respect to ring A, preferable positions are 8-, 9-

REFERENCES:
Heterocyclic Chem., vol. 28, No. 7, pp. 1809-1812.
Med. Chem. Res., 3, pp. 44-51 (1993).
Anzini. ". . . quinoline derivatives with high affinity . . . for 5-HT3 serotonin sites." Chem Abs 119:173996 1993. c!quinolin-7(H) ones." Chem Abs 119:117077 1993.
Quraishi. Synthesis and biol. act. of some new
Anzini. ". . . quinoline derivatives as potential 5-HT receptor ligands." J. Heterocyclic Chem, (28), 1809, 1991.
Chemical Abstracts, vol. 119, No. 17, Oct. 25, 1993; Abstract No. 173996h.

Affiliated with

Also associated with

Rating

Condensed-Indan derivatives and pharmaceutically acceptable salt does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Condensed-Indan derivatives and pharmaceutically acceptable salt, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Condensed-Indan derivatives and pharmaceutically acceptable salt will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-52326